Approach to Pregnancy with Jaundice
When a pregnant patient presents with jaundice, immediately measure total serum bile acids (TSBA), ALT/AST, bilirubin, and assess for life-threatening pregnancy-specific conditions (pre-eclampsia/HELLP, acute fatty liver of pregnancy) that require urgent delivery planning. 1
Initial Diagnostic Framework
The approach must differentiate between three categories:
1. Pregnancy-Specific Liver Diseases (Most Critical)
These conditions directly impact maternal and fetal mortality and require immediate recognition:
- Intrahepatic Cholestasis of Pregnancy (ICP): Diagnosed by TSBA >10 μmol/L with pruritus, typically in 2nd/3rd trimester 2
- Pre-eclampsia/HELLP syndrome: Look for hypertension, proteinuria, microangiopathic hemolysis, thrombocytopenia 1
- Acute Fatty Liver of Pregnancy (AFLP): Medical emergency with marked aminotransferase elevation, coagulopathy, hypoglycemia 2, 1
- Hyperemesis gravidarum: Usually 1st trimester with severe vomiting, weight loss, rarely causes jaundice 3
2. Pre-existing or Coincidental Liver Disease
- Viral hepatitis (check HBV, HCV, HAV serology)
- Autoimmune hepatitis (AMA, ANA, SMA)
- Choledocholithiasis/biliary obstruction (liver ultrasound)
- Drug-induced liver injury 1
3. Hemolytic Causes
- Check complete blood count for microangiopathic hemolysis
- Distinguish conjugated vs unconjugated hyperbilirubinemia 4
Algorithmic Diagnostic Approach
Step 1: Immediate Laboratory Assessment
- TSBA (non-fasting preferred in pregnancy)
- ALT/AST, bilirubin (total and fractionated), GGT, alkaline phosphatase
- Complete blood count with peripheral smear
- Coagulation profile (PT/INR)
- Albumin, creatinine
- Blood pressure and urinalysis for proteinuria 1
Step 2: Risk Stratification Based on Results
Group A (TSBA normal, ALT/AST normal):
- If pruritus persists, repeat TSBA and liver enzymes every 2-3 weeks before 32 weeks, then weekly
- Consider non-hepatic causes of jaundice
Group B (TSBA normal, ALT/AST elevated):
- Exclude viral hepatitis, autoimmune hepatitis, drug-induced injury
- Perform liver ultrasound to exclude biliary obstruction
- Consider pre-eclampsia, HELLP, AFLP based on clinical context
- Repeat testing every 2 weeks before 32 weeks, then weekly 1
Group C (TSBA elevated):
- This is the highest risk group for fetal mortality
- Weekly TSBA and liver function monitoring mandatory
- Initiate ursodeoxycholic acid (UDCA) 10-15 mg/kg/day 2, 1
Step 3: Imaging
- Abdominal ultrasound: Safe at any gestation; evaluates for gallstones, biliary obstruction, liver masses 1
- MRCP: Safe in pregnancy if biliary pathology suspected 1
- CT abdomen: Consider if AFLP suspected (shows reduced liver density from fatty infiltration) 5
Critical Management Decisions Based on Etiology
For Intrahepatic Cholestasis of Pregnancy:
TSBA 10-40 μmol/L:
- Start UDCA (may reduce spontaneous preterm birth)
- Weekly monitoring
- Consider delivery at 39 weeks 1
TSBA >40 μmol/L:
- Strongly recommend UDCA (reduces spontaneous preterm birth and may protect against stillbirth)
- Weekly TSBA monitoring
- Plan delivery at 35-37 weeks 1
TSBA >100 μmol/L:
- Recommend delivery from 35 weeks gestation (stillbirth risk increases markedly from 35 weeks in this group) 1
For Pre-eclampsia/HELLP/AFLP:
These are medical emergencies requiring multidisciplinary planning for delivery and possible liver transplantation evaluation. 2 Daily aspirin prophylaxis should have been started at 12 weeks for at-risk patients, but this is obviously too late at presentation.
For Choledocholithiasis/Cholangitis:
- ERCP is safe during pregnancy (fetal radiation <0.1-0.5 mGy, well below 50 mGy threshold for malformation)
- Ideally perform in 2nd trimester, but don't delay if patient/fetal health at risk 2, 1
- Cholecystectomy via laparoscopy is safe and standard of care, ideally in 2nd trimester 2
Common Pitfalls to Avoid
- Don't assume all jaundice in pregnancy is benign ICP - Always exclude HELLP, AFLP, and pre-eclampsia first as these require immediate delivery
- Don't use fasting bile acids - Non-fasting TSBA is preferred in pregnancy 1
- Don't ignore rising TSBA even if initially normal - Bile acids can increase with advancing gestation; weekly monitoring is essential after 32 weeks 1
- Don't delay ERCP or cholecystectomy if clinically indicated - Both are safe in pregnancy when maternal/fetal health is threatened 2, 1
- Don't forget to recheck liver tests 3 months postpartum - If abnormalities persist, investigate for underlying chronic liver disease 1
Key Monitoring Parameters
- Before 32 weeks: TSBA and LFTs every 2-3 weeks if symptomatic
- After 32 weeks: Weekly TSBA and LFTs mandatory
- Fetal monitoring: Increased surveillance for TSBA >40 μmol/L
- Stop UDCA at delivery, taper over 2-4 weeks postpartum if symptoms persist 1